ReNeuron looks to Phase II with stem cell stroke therapy
This article was originally published in Clinica
Executive Summary
UK company ReNeuron has filed an early application to the UK MHRA to begin a Phase II clinical trial with its stem cell-based therapy ReN001 for stroke, after encouraging safety results from the Phase I study were reported earlier this year.